Boston Scientific Corp (BSX) · Oct 28, 2026 · Earnings
Beat — Adjusted EPS $0.73 vs ~$0.72 consensus; revenue $5.138B vs ~$5.06B consensus
Boston Scientific earnings modestly beat Q3 expectations, but its guidance cut points to a tougher recovery after the cyber incident.
Boston Scientific is a large medical-device maker trying to extend its growth through cardiovascular innovation, new product launches and an expanding pipeline while repairing operations after the August 2026 cybersecurity disruption. Operations were reported restored in September, but the incident was already expected to weigh on the second half.
| Metric | Q3 2026 | Comparison | Read |
|---|---|---|---|
| Revenue | $5.138B | ~$5.06B consensus | Beat |
| Adjusted EPS | $0.73 | ~$0.72 consensus | Beat |
| Organic sales growth | 1.5% | 7.0% in Q2 2026 | Sharp slowdown |
| Q4 organic sales guidance | (3.0)% to (1.0)% | Prior Q3 guidance: 3.0% to 5.0% | Cut |
| FY 2026 organic sales guidance | ~3.75% | Prior: 5.0% to 6.0% | Cut |
| FY 2026 adjusted EPS guidance | $3.16–$3.18 | Prior: $3.28–$3.32 | Cut |
The quarter narrowly beat lowered expectations, but the underlying growth engine slowed materially. Revenue of $5.138 billion rose just 1.5% organically, while adjusted EPS was $0.73 versus the published consensus of roughly $0.72 and revenue consensus of roughly $5.06 billion. The beat is real, but small; it does not offset the fact that organic growth fell sharply from the 7% pace reported in the second quarter. 〔0〕
The guidance cut is the more important signal. Management now expects fourth-quarter sales to decline 1% to 3% and reduced full-year organic growth guidance to approximately 3.75%, from the previous 5% to 6% range. Full-year adjusted EPS guidance fell to $3.16–$3.18 from $3.28–$3.32. That is a substantial reset to the recovery story, even though the cyber disruption was already known. 〔1〕
The weakness is concentrated in several operating lines, not just accounting noise. Urology declined 3.1% organically and Endoscopy declined 0.6%, while Cardiovascular grew only 1.9%; Neuromodulation was the standout at 13.0%. Meanwhile, GAAP operating income fell to $828 million from $1.048 billion, with litigation, restructuring and impairment charges adding pressure.
The innovation pipeline remains active, but it is not yet repairing the near-term demand hole. The filing highlights new trial enrollment, FDA clearances and an AI collaboration with Heartflow, which support the long-term portfolio strategy. But those developments are future growth options; the immediate business story is that the cyber-related disruption and broader segment softness have pushed the company into a negative fourth-quarter outlook.
Bottom line: Boston Scientific beat a lowered Q3 bar, but the material guidance cuts make this a mixed earnings release. The filing says the operational recovery is not yet translating into the growth or earnings trajectory investors previously expected.
Q4 report, late January 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!